OPHI CollPlant Biotechnologies Ltd
Orthopedic, Prosthetic & Surgical Appliances & Supplies · Nasdaq · SEC CIK 1631487 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY360.4%
TTM net income YoY30.8%
TTM EPS YoY35.2%
Revenue 3-yr CAGR99.4%
Net income 3-yr CAGR—
Margins
Gross margin64.8%
Operating margin-484.3%
Net margin-484.6%
FCF margin-398.4%
EBITDA margin-445.8%
Returns
ROE-117.6%
ROA-77.9%
ROIC (approx.)-886.8%
Asset turnover0.16x
Leverage & solvency
Liabilities / assets43.6%
Debt / equity0.00x
Current ratio2.53x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.82x
Accruals ratio-14.0%
Payout ratio—
Capex / revenue1.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2025Q22025-06-30 | 2024Q22024-06-30 | 2023Q22023-06-30 | 2022Q22022-06-30 | 2021Q22021-06-30 | 2020Q22020-06-30 | 2019Q22019-06-30 | 2018Q2*2018-06-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $179,000 | $249,000 | $10.18M | $66,000 | $691,000 | $823,000 | $606,000 | $182,000 |
| Cost of revenue | $186,000 | $536,000 | $615,000 | $43,000 | $429,000 | $748,000 | $463,000 | $67,000 |
| Gross profit | -$7,000 | -$287,000 | $9.57M | $23,000 | $262,000 | $75,000 | $143,000 | $115,000 |
| R&D expense | $2.01M | $2.70M | $2.57M | $2.60M | $1.90M | $1.00M | $1.08M | $641,000 |
| SG&A expense | $1.16M | $1.42M | $1.32M | $1.61M | $1.42M | $986,000 | $820,000 | $863,000 |
| Operating income | -$3.18M | -$4.41M | $5.68M | -$4.18M | -$3.06M | -$1.91M | -$1.76M | -$1.39M |
| Interest expense | — | — | — | — | — | — | $64,000 | $247,000 |
| Net income | -$3.35M | -$4.21M | $5.76M | -$4.29M | -$3.04M | -$1.97M | -$1.25M | -$1.55M |
| EPS (basic) | 0.28 | 0.37 | 0.51 | -0.39 | -0.30 | -0.28 | 0.27 | 0.36 |
| EPS (diluted) | 0.28 | 0.37 | 0.49 | -0.39 | -0.30 | -0.28 | 0.27 | 0.36 |
| Weighted avg. shares (diluted) | 11.84M | 11.45M | 11.78M | 11.09M | 10.20M | 6.96M | 4.66M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $11.43M | $18.92M | $22.28M | $36.29M | $17.68M | $3.85M | $1.91M | $2.56M |
| Receivables | — | $250,000 | $10.16M | $9,000 | $277,000 | $321,000 | $611,000 | $423,000 |
| Inventory | $553,000 | $439,000 | $1.55M | $1.36M | $940,000 | $730,000 | $958,000 | $642,000 |
| Current assets | $12.62M | $20.34M | $34.86M | $38.27M | $49.77M | $5.49M | $3.61M | $4.22M |
| PP&E, net | $1.86M | $2.56M | $2.93M | $2.92M | $2.12M | $2.25M | $2.24M | $1.48M |
| Intangibles | $102,000 | $159,000 | $216,000 | $235,000 | $164,000 | — | — | — |
| Total assets | $17.44M | $26.57M | $41.57M | $44.41M | $55.02M | $10.95M | $9.55M | $6.26M |
| Current liabilities | $2.74M | $3.24M | $2.78M | $2.36M | $2.93M | $2.18M | $3.30M | $1.07M |
| Long-term debt | — | — | — | — | — | — | — | $58,000 |
| Total debt | — | — | — | — | — | — | — | $58,000 |
| Total liabilities | $4.93M | $5.84M | $5.53M | $4.91M | $5.58M | $5.17M | $7.72M | $2.71M |
| Shareholders' equity | $12.51M | $20.73M | $36.04M | $39.51M | $49.44M | $5.78M | $764,000 | $3.54M |
| Net debt | — | — | — | — | — | — | — | -$2.51M |
| Shares outstanding | 12.72M | 11.45M | 11.41M | 10.77M | 10.26M | 6.47M | — | — |
| Cash flow statement | ||||||||
| Operating cash flow | — | — | — | — | — | — | — | — |
| Stock-based compensation | $356,000 | $490,000 | $338,000 | — | — | $477,000 | $289,000 | — |
Free plan shows the latest 8 periods; Pro shows all 9 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.